Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
about
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.The use of eculizumab in renal transplantation.Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathyAntiphospholipid syndrome in renal transplantation.Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Eculizumab in Transplant-Associated Thrombotic Microangiopathy.Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndromeThe Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Defective complement inhibitory function predisposes to renal disease.Top 10 clinical research developments in antiphospholipid syndrome.Novel immunosuppressive agents in kidney transplantationAntiphospholipid syndrome: an update.Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation.Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes.Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement.Abdominal pain, flank pain, blurry vision, and lower extremity weakness in a 16-year-old female.Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation
P2860
Q33403607-74724CF5-4170-4DAF-9013-C85716AA3300Q33406570-9C1CFC58-C0FC-4BEF-BE93-537938DE27C1Q33408360-897A808F-D735-4963-9656-D1D716D8DC56Q33411321-2BE49854-5391-426E-88EC-2D99B3C115ABQ33413394-A359D1DD-3A94-4530-94F1-9099B74E549BQ33419171-A8008020-2550-42D5-A49F-908C4A779098Q33419693-4275D433-7800-41E7-A72E-902ED2C98181Q33424902-33326E54-F73B-4BFB-9C75-6BBACFE4A53FQ33425079-54FD36F5-FB2C-4FE8-9C55-D70C7C43C776Q33427917-6C2C04B5-BBFB-4D76-836E-38387CA51A1EQ33431097-8C293430-F151-47AC-BE51-1D759214DCBFQ33705135-5CE12BFE-3C5D-437E-A6A9-419D636A0F97Q34465747-C3D7656A-A08F-4E08-AA91-38ABE2A63943Q38135335-531851D7-33E8-4851-ACB1-B4F0E0E0F416Q38176005-50A9912C-42E7-436D-803D-D3DC0548C3C5Q38410376-A40CCF12-4996-4205-82C2-DA39B275A12FQ38544987-048528ED-432E-4BC3-A1D1-B2AABB28148AQ38794847-8DA40A47-873A-4DB9-8F9C-2849D4177EAAQ38930294-6576CA55-E7CB-4B33-B975-B9F1746FBD02Q39968188-B4CF6FE2-A15E-47F1-AA13-14CB6D3B12C8Q42086661-7B75C6E9-6F5F-42F9-8741-43451E86EF53Q42553965-AC8D67B5-861E-4D36-911C-ACA2F7F5B576Q47640137-6963BA79-DEB2-4185-B9EE-747B95E338E9Q47998109-534E2631-1C64-4DDD-9C6E-CCABBCA4F5E1Q48380302-48CD2D9E-D30A-42FA-ADC7-D303D52C3E6EQ51144375-8E155478-8657-4F55-9600-951A3A44E439Q55177568-07FE3B82-6D7F-44AB-9EDE-588A21B5386DQ58048140-4FCF0521-E7A5-474F-98F1-CBF469CB2776
P2860
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@ast
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@en
type
label
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@ast
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@en
prefLabel
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@ast
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@en
P2093
P2860
P1476
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
@en
P2093
P-Y Martin
S Ferrari-Lacraz
P2860
P304
P356
10.1111/J.1600-6143.2011.03696.X
P407
P577
2011-08-10T00:00:00Z